The results of clinical studies ofradiopharmaceuticals based on affibody molecules, ADAPTs, and DARPins for SPECTand PET have demonstrated good tolerability of the compounds, their rapidexcretion from the body, and the possibility to differentiate tumor sitesdepending on the HER2/neu status. Here, ERBB2 is linked to neoplasm.